Market Research Future

Cystic Fibrosis Market Is Expected to Grow at a CAGR of 13.5% Till 2022

Market Research Future Published a Cooked Research Report on Global Cystic fibrosis Research Report. By Treatment Method - Global Forecast till 2022.

 

Pune, India -- (SBWIRE) -- 12/12/2018 -- Cystic fibrosis (CF) is a chronic as well as genetic disease that affects the progress of the entire body that can cause to severe disability and early death in some cases. Market Research Future (MRFR) has published a research report about the global cystic fibrosis market that anticipates a great increase in this market at 13.8% CAGR (Compound Annual Growth Rate) between 2016 and 2022. In terms of value, the market is expected to be worth the US $ 1,192.2 mn by the end of the forecast period.

The compelling factors ensuring an enriching growth for the global cystic fibrosis market include the development of new drugs & therapies and financial support from Cystic Fibrosis Foundation (CFF) in research and development of cystic fibrosis drugs. However, the high costs of many cystic fibrosis treatment procedures can dampen the speed of market growth.

Segmentation:

The global cystic fibrosis market has been segmented on the basis of diagnostic test, drug type, treatment, and lastly, region. Based on the diagnostic test, this market has been segmented into chest X-Ray, Computed Tomography (CT) scan, immunoreactive trypsinogen (IRT) test, pulmonary function test, sputum test, and sweat chloride test.

Request Sample copy at https://www.marketresearchfuture.com/sample_request/1825

By drug type, the market has been segmented into biologics and small molecules. The treatment-based segmentation segments the market into medical therapy, surgical treatment, and others.

Key Players:

The key players in the global cystic fibrosis market include AbbVie (USA), Gilead Sciences (USA), F. Hoffmann-La Roche (Switzerland), Forest Laboratories (USA), Genentech (USA), Novartis (Switzerland), Pharmaxis (Australia), and Vertex Pharmaceuticals (USA).

Latest Industry News:

In an innovative partnership, NuvoAir and London's Royal Brompton Hospital are helping cystic fibrosis patients to conduct tests at home. With Air Next simple-to-use spirometer, patients can conduct tests on their own, with an app called Aria measure the state of the patient's lungs and predict worsening. Aria has been developed by Nuvo Air. Patients can analyze the data on the app itself can share them with the health care team. 4 DEC 2018
According to a study published in the New England Journal of Medicine, Cystic Fibrosis lung function can be improved with Triple Therapy on the basis of chloride sweat concentrations where VX-659 is added to ivacaftor and tezacaftor. 9 DEC 2018
Regional Analysis:

The regional segmentation of the global cystic fibrosis market segments the market into regional markets known as North America, Europe, Asia Pacific, and the Middle East & Africa (MEA). North America is the largest regional market due to the availability of advanced medical facilities, large patient population, overall technological advancement, presence of strong economic condition, the presence of many key market players, and lastly, the availability of government funding for the research institutions on research and development (R & D) the medical sector. The strongest economies in this region that can be important markets are the United States of America (USA) and Canada.

Europe is the second largest regional market as it has the second highest patient population. The advanced medical facilities are available in most of the European countries. In this region, the strongest economies that can be perfect markets are France, Germany, and the United Kingdom (UK).

The Asia Pacific is a smaller market for cystic fibrosis than North America and Europe due to limited information and majority cystic fibrosis cases going undiagnosed. Due to limited healthcare facilities, the market is limited. Countries that have the potential to become lucrative markets by improving healthcare facilities are China, India, and Japan. China and Japan have the least population of cystic fibrosis patients.

The MEA region has the least market share due to poor countries, lack of awareness, lack of education, low standard of medical facilities, lack of healthcare facilities, and majority governments not considering healthcare a priority.

Browse Complete 85 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com